Issue of Equity

Cyprotex PLC

("Cyprotex" or "the Company")

Cyprotex PLC (AIM: CRX), the drug discovery technology and information company, today announces that it has issued 175,000 new ordinary shares of 0.1p each ("new Ordinary Shares") pursuant to the exercise of options.

The issue of the new Ordinary shares is subject to the new Ordinary Shares being admitted to trading on AIM, application for which has been made. Trading in the new Ordinary Shares, which will rank pari passu in all respects with the existing ordinary shares, is expected to commence on 16 January 2013. Following admission of the new Ordinary Shares, the total number of ordinary shares in issue will be 223,862,485. Therefore, the total number of voting rights in the Company will be 223,687,485.

- Ends -

For further information:

Notes to Editors

About Cyprotex PLC

Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, Boston in the US and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners ranging from small biotechs to large pharma companies. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services and predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction. For more information, see www.cyprotex.com.